TREVENA INC: Nasdaq/NYSE listing notice — Trevena receives Nasdaq deficiency notice for bid price below $1; has 180 days to cure

TREVENA INC

On April 21, 2023, Nasdaq notified Trevena that its common stock closed below $1.00 for 30 consecutive business days.
Company has until October 18, 2023 (180 calendar days) to regain compliance under Nasdaq Listing Rule 5550(a)(2).
To regain compliance, closing bid price must be at least $1.00 for ten consecutive business days.
If not compliant by Oct 18, company may qualify for an additional 180-day cure period if it meets other listing standards.
Stock continues trading on Nasdaq Capital Market under symbol TRVN; delisting risk exists if not cured.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TREVENA INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 21, 2023, Trevena, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the listing of the Company’s common stock, which will continue to trade on The Nasdaq Capital Market under the symbo

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-048474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.